The Hypothesis on the Prediction of Treatment Response with Buspirone Augmentation along with Serotonergic Antidepressant in Patients with Major Depressive Disorder Using Loudness Dependence of Auditory Evoked Potentials: Two Cases and Review of the Literature for Evidence
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Some studies have shown that augmenting buspirone with antidepressant has similar efficacy as the combination with two antidepressants in patients with major depressive disorder (MDD). Some researchers assume that the antidepressant boosting effect of buspirone is revealed under a poop-out state, which means a phenomenon where some patients having an initial response to an antidepressant may worsen or not improve any more even though they continue treatment because of serotonin depletion. Loudness dependence of auditory evoked potential (LDAEP) is a reliable marker of central serotonergic activity, and is inversely correlated with central serotonergic activity. Thus LDAEP will be a biological marker for prediction of treatment response with buspirone augmentation with SSRI because it can measure central serotonergic activity such as serotonin depletion. Two cases will be introduced and the literature evidence about whether LDAEP can predict the treatment response of buspirone augmentation in patients with MDD will be reviewed.
Abstract
Some studies have shown that augmenting buspirone with antidepressant has similar efficacy as the combination with two antidepressants in patients with major depressive disorder (MDD). Some researchers assume that the antidepressant boosting effect of buspirone is revealed under a poop-out state, which means a phenomenon where some patients having an initial response to an antidepressant may worsen or not improve any more even though they continue treatment because of serotonin depletion. Loudness dependence of auditory evoked potential (LDAEP) is a reliable marker of central serotonergic activity, and is inversely correlated with central serotonergic activity. Thus LDAEP will be a biological marker for prediction of treatment response with buspirone augmentation with SSRI because it can measure central serotonergic activity such as serotonin depletion. Two cases will be introduced and the literature evidence about whether LDAEP can predict the treatment response of buspirone augmentation in patients with MDD will be reviewed.
참고문헌 (19)
- Ionescu DF, "Pharmacological approaches to the challenge of treatment-resistant depression", Dialogues Clin Neurosci, 17, pp.111~126 (2015)
- Loane C, "Buspirone: what is it all about?", Brain Res, 1461, pp.111~118 (2012)
- Trivedi MH, "Medication augmentation after the failure of SSRIs for depression", N Engl J Med, 354, pp.1243~1252 (2006)
- Targum SD, "Identification and treatment of antidepressant tachyphylaxis", Innov Clin Neurosci, 11, pp.24~28 (2014)
- Morrissette DA, "Modulating the serotonin system in the treatment of major depressive disorder", CNS Spectr, 19(Suppl 1), pp.57~67 (2014)
- Stahl SM, "Serotonergic drugs for depression and beyond", Curr Drug Targets, 14, pp.578~585 (2013)
- Hegerl U, "Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission : a new hypothesis", Biol Psychiatry, 33, pp.173~187 (1993)
- 이승환, "높은 N100 진폭경사를 보이는 두 환자의 세로토닌 재흡수 억제제 이상반응", 대한정신약물학회지, 19(6), pp.341~347 (2008), 대한정신약물학회
- Pogarell O, "Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder", Neuropsychopharmacology, 29, pp.1910~1917 (2004)
- Juckel G, "Auditory-evoked potentials as indicator of brain serotonergic activity--first evidence in behaving cats", Biol Psychiatry, 41, pp.1181~1195 (1997)
- Hegerl U, "Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?", J Affect Disord, 62, pp.93~100 (2001)
- Nathan PJ, "Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential(LDAEP)marker of central serotonin function", Hum Psychopharmacol, 21, pp.47~52 (2006)
- Lee TW, "Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression", J Psychiatry Neurosci, 30, pp.202~205 (2005)
- Mulert C, "Comparison between the analysis of the loudness dependency of the auditory N1", P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression, 2002, pp.113, 1566~1572
- Gallinat J, "The loudness dependency of the auditory evoked N1", P2-component as a predictor of the acute SSRI response in depression, 2000, pp.148, 404~411
- Mulert C, "Prediction of treatment response in major depression : integration of concepts", J Affect Disord, 98, pp.215~225 (2007)
- Juckel G, "Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder", J Clin Psychiatry, 68, pp.1206~1212 (2007)
- Lee BH, "Prediction of long-term treatment response to selective serotonin reuptake inhibitors(SSRIs)using scalp and source loudness dependence of auditory evoked potentials(LDAEP)analysis in patients with major depressive disorder", Int J Mol Sci, 16, pp.6251~6265 (2015)
- Park YM, "The loudness dependence of the auditory evoked potential(LDAEP)as a predictor of the response to escitalopram in patients with generalized anxiety disorder", Psychopharmacology(Berl), 213, pp.625~632 (2011)